Skip to content

Asset turnover at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
0.3×+0.1×
ALN
Alnylam PharmaceuticalsALNY
0.9×+0.3×
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
0.0×
Beam Therapeutics logo
Beam TherapeuticsBEAM
0.1×+0.1×
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
0.3×+0.1×
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
0.1×+0.1×

Other financials

Income statement

See full
Revenue$15.0M-9.5%
Operating income-$100.5M+16.8%
Net income-$96.2M+15.8%
EPS (diluted)-$0.81+26.4%

Balance sheet

See full
Cash & equivalents$134.7M+6.2%
Total debt$80.5M-32.5%
Total equity$620.9M-20.4%
Total assets$758.8M-23.1%

Cash flow

See full
Operating cash flow-$117.3M+21.2%
CapEx$79.0K-89.3%
Free cash flow-$117.4M+21.5%

Valuation

See full
Market cap$2.13B+106%
Enterprise value$2.08B+100%
P/S32.2×+9.5×

Profitability

See full
Operating margin-636.6%-202pp
Net margin-597%-194pp
FCF margin-550.2%-140pp

Returns & leverage

See full
Return on equity-56.3%-1.5pp
Debt / equity0.1×0.0×
Current ratio6.1×+1.2×

Where this comes from

Calculated from Intellia Therapeutics’s reported figures.

Based on trailing twelve months.

The official record: Intellia Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Intellia Therapeutics's asset turnover.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Intellia Therapeutics's asset turnover?
Intellia Therapeutics (NTLA) reported asset turnover of 0.1× in Q1 2026.
How has Intellia Therapeutics's asset turnover changed year-over-year?
Intellia Therapeutics's asset turnover increased by 86.7% year-over-year, from 0× to 0.1×.
What is the long-term trend for Intellia Therapeutics's asset turnover?
Over 5 years (2020 to 2025), Intellia Therapeutics's asset turnover has grown at a -10.3% compound annual growth rate (CAGR), from 0.1× to 0.1×.
What does asset turnover mean?
Trailing-twelve-month revenue divided by average total assets. Measures how many dollars of sales each dollar of assets generates — the efficiency leg of the DuPont decomposition of ROE.